Biodesix Webinar | Digital Event
Advancements in Proteomics & Machine Learning Techniques for
Diagnostic Test Discovery
Senior Vice President, Research & Translational Sciences
Tuesday October 12, 2021
11:00am ET | 8:00am PT | 9:00am MT
This October Biodesix Webinar will Cover:
Advancements in Proteomics & Machine Learning Techniques for Diagnostic Test Discovery
Join Biodesix for this interactive webinar focused on how new technologies and statistical methods are enabling us to further understand the biological underpinnings of diagnostic tests.
This exclusive event will provide leaders in pharma and biotech with deep-dive discussions to stay ahead of the curve by exploring machine learning techniques and how these can be used to better understand data sets and drive the discovery of diagnostic tests.
The webinar is designed to equip you with expert insight necessary for successfully understanding the benefits of using proteomic information and artificial intelligence to improve your clinical trials. You will also have the opportunity to ask your questions on these topics in a live and interactive Q&A!
WHAT WILL YOU DISCUSS?
- Dive deep into how advancements in proteomics and artificial intelligence have evolved to better understand the biological underpinnings of diagnostic tests
- Explore how Shapley Values can help explain unique biological mechanisms for each patient within subgroups
- Hear about Biodesix’s pipeline diagnostics tests for lung cancer/diseases and discover how they utilize proteomic information and artificial intelligence to help guide clinical decisions
Robert W. Georgantas III, Ph.D. has served as our Senior Vice President of Research and Translational Science since August 2019. From 2014 to 2019, prior to joining Biodesix, Dr. Georgantas worked at AbbVie where he served as Director of Immunology Programs and Biomarkers within the Genomics Research Center of Excellence, a group of experts tasked with applying genetics, genomics, epigenetics, and metagenomics to inform the product pipeline primarily regarding new target discovery, biomarkers for clinical trials, and asset positioning. From 2008-2014, he worked in the Department of Translational Science at Medimmune/Astra-Zeneca. Before he entered/joined industry, he was a faculty member in the Department of Oncology at the Johns Hopkins School of Medicine. Dr. Georgantas is recognized as a leader of immunology translational science and strategy. Dr. Georgantas completed his Ph.D. in pharmacology and molecular medicine at the Johns Hopkins University School of Medicine.
Biodesix is a leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease. Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies and leverage our proprietary artificial intelligence platform to discover innovative diagnostic tests for clinical use. Our technology agnostic approach allows for a broader and more holistic understanding of each patient’s disease state. Additionally, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. See more information at www.biodesix.com.